MedWaves, Inc. AveCure(TM) microwave coagulation-ablation (MWA) system uses microwave energy to volumetrically coagulate-ablate (destroy) soft-tissue lesions (abnormal structures) safely, effectively, precisely and with repeatability. The system has successfully treated over one-thousand patients worldwide, including lesions in bone, kidney, liver, lung and pancreas. The company plans to bring its technology to treat lesions in other locations in the body. The company's technology makes available treatment options for many cancer patients in either early or late stage and helps those who are running out of options. MedWaves AveCure(TM) Microwave Coagulation-Ablation System overcomes the limitations of other microwave and radiofrequency (RF) thermal ablation technologies to destroy lesions safely, effectively, precisely and with repeatability and uniformity. It is the only system approved in the market to provide clinicians with patented fully integrated real-time temperature, both forward and reverse-power feedback to control energy delivery intelligently. The system, which consists of a generator, extension cable set, and an array of single-patient-use microwave-probe devices, enables the surgeons and interventional radiologists to treat soft-tissue lesions, such as tumors, safely and easily, with confidence. This single-patient-use device provides a continuous revenue stream. MedWaves AveCure(TM) Microwave Coagulation-Ablation System has also received USFDA approval for sales in the United States and CE mark for sales in Europe.

MedWaves, Inc. announced that it received Korean Food and Drug Administration (KFDA) approval to import and sell products. MedWaves is in close coordination with its South Korean distributor-partner in scheduling and conducting clinical evaluations for sales of its AveCure(TM) system in key South Korean hospitals.